Achieving a better cure for cancer

As of today, CiMaas is located at the Schleperweg 36, in Maastricht (NL). In this facility we continue our work on (GMP grade) feeder cells and NK cell technology for the benefit of cancer patients.

Thanks to an investment from 819 Evergreen Fund I, we are pleased to be able to continue working on our ambitions: cure cancer patients by making Natural Killer cells a reality. Our activities will be realized in Maastricht.

Under the agreement, CiMaas will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical cord blood-derived NK cells. Conversely, CYTEA BIO will supply CiMaas with Pin™ antibodies for the pre-arming of CiMaas NK cells to assess the benefit it brings and the opportunity to pursue a longer-term partnership.